Kocher S, Muller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review[J]. Int J Antimicrob Agents, 2010, 36(2): 106-110.
[3]
Welsh KJ, Abbott AN, Lewis EM. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin[J]. J Clin Microbiol, 2010, 48(3) : 894-899.
Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Grampositive infections in neonates[J]. Pediatr Infect Dis J, 2003, 22(9): S158-S163.
Boselli EP. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator associated pneumonia[J]. Crit Care Med, 2005, 33(7) : 1529- 1534.
[11]
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment[J]. J Antimicrob Chemother, 2011, 66 (Suppl 4): iv7-iv15.
[12]
Langgartner M, Mutenthaler A, Haiden N, et al. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants[J]. BMJ Case Rep, 2009, 11(5): 1217.
[13]
Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptides or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomized controlled trials [J]. Lancet Infect Dis, 2008, 8 (1) : 53-66.
